Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Home About Us My Account Personal Library Customer Service    
Welcome Guest
(login/register)
US: 800.298.5699
Int'l: +1.240.747.3093
Quick Search
Advanced Search >
Research Assistance
Send us a request >
Latest Research by Email
Receive email alerts of new market research reports in your industry.
Sign Up Today >
Home > Back to Publisher > Report Information Email a colleague | Printer format

Parallel Trade in Pharmaceuticals

Urch Publishing
October 1, 2003
133 Pages - Pub ID: URC930773
 
Questions about this report >
Order by fax >
XE.com
Abstract

Table of
Contents
Search Inside
this Report
Related Reports


Parallel Trade in Pharmaceuticals

 
Parallel trade or parallel importation is the cross-border trade in a particular product, through a route that the manufacturer may not have originally intended. As many manufacturers operate a system whereby they sell their products at different prices in different markets, there is an incentive for those wishing to reduce the costs of their purchases to seek these products from the lower-priced markets. As the demand for cheaper products has grown, parallel trade businesses have flourished. By sourcing products from lower-priced markets to sell to consumers in higher-priced markets, these companies can offer significant savings to consumers, who thereby have an alternative to the price that the product is being sold at in their country by the original manufacturer.

This, 60,000 word strategic management, publication provides the valuable market overview and data that all pharmaceutical companies will find essential in their business.

Understand the development in this fast-moving sector:

  • Examines the impact of forthcoming EU enlargement as a new source of cheaper product
  • Describes how high drug prices in the United States is opening up the potential for imports from Canada and Mexico
  • Asks whether parallel trade will become a global issue as countries like Kenya and the Philippines experiment
  • Discusses whether parallel imports are influencing big pharma’s R&D spend
  • Latest thinking on the exhaustion of intellectual property rights in international law

Comprehensive insight into the major issues including:

  • Why price differential is not the only factor that causes parallel trade
  • Case studies and descriptions of legal battles in the EU that have been fought over the last 30 years
  • Why EU legislation and governments encourage parallel imports
  • How the AIDS crisis has become the biggest issue for governments, ethical pharmaceutical companies and parallel traders alike
  • The WTO’s role and compulsory licensing Economic arguments for and against the existence of parallel trade in pharmaceuticals


Related Reports:
Country Forecast Pakistan November 2009 Updater
Country Forecast El Salvador November 2009 Updater
Country Forecast Vietnam November 2009 Updater
Country Risk Service El Salvador November 2009
Country Forecast Hong Kong November 2009 Updater
Country Risk Service Hong Kong November 2009
Country Forecast Denmark November 2009 Updater
Country Risk Service Malaysia November 2009
Country Risk Service Uganda November 2009 Updater
Country Forecast Malaysia November 2009 Updater

Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 2